Uncategorized
Q1 earnings take off, Lilly strikes many deals, Regeneron notches historic approval, FDA raises questions
Q1 earnings take off, Lilly strikes many deals, Regeneron notches historic approval, FDA raises questions
Sanofi and Novartis kick off the heart of earnings season; Lilly strikes its fourth pact in as many weeks; Regeneron earns landmark approval for a gene therapy for a type of genetic deafness, and also strikes a White House deal; FDA asks Amgen to withdraw Tavneos and, separately, issues Commissioner’s National Priority Vouches to three unnamed psychedelics companies. Read More